You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

171 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Jun 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant, Adjuvant
Jun 2019
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Jul 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jul 2019
Regimen
Cancer Type:
Sarcoma, 
Osteogenic / Bone
Intent: Adjuvant, Neoadjuvant, Palliative
Sep 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell, 
Small Cell
Intent: Neoadjuvant, Adjuvant, Curative, Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    prednisone
Jul 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    prednisone
Jul 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jul 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
ODB Limited Use
    fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)
ODB - General Benefit
    cyclophosphamide - oral tablets
Jun 2019

Pages